Fanta Korinan, Daba Fekede Bekele, Asefa Elsah Tegene, Chelkeba Legese, Melaku Tsegaye
Department of Clinical Pharmacy, Institute of Health, Jimma University, Jimma, Oromia, Ethiopia.
Department of Internal Medicine, Institute of Health, Jimma University, Jimma, Oromia, Ethiopia.
Diabetes Metab Syndr Obes. 2021 Jul 15;14:3253-3262. doi: 10.2147/DMSO.S320203. eCollection 2021.
Despite the increasing burden of metabolic syndrome (MS) and ischemic heart disease in sub-Saharan Africa, data on the prevalence of MS among patients with acute coronary syndrome (ACS) from the regions are limited. Hence, this study is aimed to evaluate the prevalence and impact of MS on 30-day all-cause mortality in patients hospitalized with ACS.
We prospectively assessed 176 ACS patients, who were admitted to two tertiary hospitals in Ethiopia. MS was diagnosed based on a harmonized definition of MS. In-hospital major adverse cardiovascular events (MACE) and 30-day mortality were recorded. Multivariable cox-regression was used to identify predictors of 30-day mortality.
Among 176 ACS patients enrolled, 62 (35.2%) had MS. Majority of the patients (62.5%) were male with the mean age of 56±11.9 years. ACS patients with MS were older, presented with atypical symptoms, and they had history of hypertension, diabetes, dyslipidemia and coronary artery disease compared to those without MS. MS was also significantly associated with in-hospital MACE (30.6% vs 17.5%; p= 0.046) and 30-day mortality [adjusted hazard ratio (AHR) = 3.25, 95% CI=1.72-6.15]. The other significant predictors of 30-day mortality were pre-hospital delay >12h (HR= 4.32, 95% CI=1.68-11.100), killip class ≥2 (HR=10.7, 95% CI= 2.54-44.95), and ejection fraction <40 (HR= 2.59 95% CI=1.39-4.84).
The prevalence of MS among patients with ACS in Ethiopia is high. MS was significantly associated with high in-hospital MACE and it was an independent predictor of 30-day mortality. Initiating appropriate strategies on MS prevention and timely diagnosis of MS components could decrease the burden of ACS and improve patient's outcome.
尽管撒哈拉以南非洲地区代谢综合征(MS)和缺血性心脏病的负担日益加重,但该地区急性冠状动脉综合征(ACS)患者中MS患病率的数据有限。因此,本研究旨在评估MS在因ACS住院患者中的患病率及其对30天全因死亡率的影响。
我们前瞻性评估了176例埃塞俄比亚两家三级医院收治的ACS患者。MS根据统一的MS定义进行诊断。记录住院期间主要不良心血管事件(MACE)和30天死亡率。采用多变量Cox回归分析确定30天死亡率的预测因素。
在纳入的176例ACS患者中,62例(35.2%)患有MS。大多数患者(62.5%)为男性,平均年龄56±11.9岁。与无MS的ACS患者相比,患有MS的ACS患者年龄更大,表现为非典型症状,且有高血压、糖尿病、血脂异常和冠状动脉疾病史。MS还与住院期间MACE显著相关(30.6%对17.5%;p = 0.046)以及30天死亡率[调整后风险比(AHR)= 3.25,95%可信区间(CI)= 1.72 - 6.15]。30天死亡率的其他显著预测因素包括院前延误>12小时(HR = 4.32,95% CI = 1.68 - 11.100)、Killip分级≥2(HR = 10.7,95% CI = 2.54 - 44.95)以及射血分数<40(HR = 2.59,95% CI = 1.39 - 4.84)。
埃塞俄比亚ACS患者中MS的患病率较高。MS与住院期间高MACE显著相关,且是30天死亡率的独立预测因素。启动适当的MS预防策略并及时诊断MS的组成部分可减轻ACS负担并改善患者预后。